Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
University of Ulsan · Ulsan College · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,270
total citations
- FWCI
- 88.33
- Percentile
- 100%
- References
- 37
Citations per year
Authors
24Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Nivolumab
- Chemotherapy
- Cancer
- Population
- Clinical endpoint
- Refractory (planetary science)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.